RT Journal Article
SR Electronic
T1 Pharmacokinetics/pharmacodynamics by Race: Analysis of a Peginterferon β-1a Phase I Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.01.22272847
DO 10.1101/2022.04.01.22272847
A1 Zhao, Yuan
A1 Mokliatchouk, Oksana
A1 Ramia, Nancy F
A1 Naylor, Maria L
A1 Butts, Cherié L
YR 2022
UL http://medrxiv.org/content/early/2022/04/03/2022.04.01.22272847.abstract
AB Background Black/African-American participants are underrepresented in clinical trials but can experience a greater burden of disease, such as multiple sclerosis, than other racial groups in the United States. A phase 1, open-label, 2-period crossover study that demonstrated bioequivalence of subcutaneous (SC) and intramuscular (IM) injection of peginterferon beta-1a in healthy volunteers enrolled a similar proportion of Black/African-American and White participants, enabling a subgroup analysis comparing these groups.Methods Peginterferon beta-1a 125 μg was administered by SC or IM (1:1) injection, followed by a 28-day washout period before a second injection using the alternate method. Primary endpoints were maximum observed concentration (Cmax) and area under the concentration-time curve from Hour 0 to infinity (AUCinf). Secondary endpoints included safety, tolerability, and additional pharmacokinetic and pharmacodynamic parameters.Findings This analysis included 70 (51.5%) Black and 59 (43.3%) White participants. Black participants exhibited a 29.8% higher geometric mean Cmax of peginterferon beta-1a than White participants following SC administration and demonstrated similar values following IM administration. Black participants displayed 31.0% versus 11.8% higher geometric mean AUCinf values than White participants with SC versus IM administration. Neopterin dynamics and safety signals were similar between groups, with numerically fewer adverse events reported among Black participants.Conclusions No clinically meaningful differences were identified between Black and White participants in pharmacokinetics/pharmacodynamics or safety related to peginterferon beta-1a administration, indicating that no change in dosing regimen is warranted for Black patients with MS.Funding Funding for medical writing support was provided by Biogen Inc. (Cambridge, MA, USA).Competing Interest StatementY.Z., O.K., N.R., and C.L.B. are employees of Biogen Inc. M.L.N was an employee of Biogen Inc. at the time of these analyses.Funding StatementThis study was funded by Biogen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Midlands Independent Review Board at each study site approved the study protocol, and the study was conducted in accordance with the International Council for Harmonisation Guidelines on Good Clinical Practice and the World Medical Association Declaration of Helsinki. All participants signed and dated informed consent forms prior to any evaluations for study eligibility.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available. The authors fully support sharing whenever possible. Requests for de-identified data should be made to Biogen via established company data-sharing policies and processes detailed on the website http://clinicalresearch.biogen.com/.